Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Current therapeutic targets for the treatment of Alzheimer's disease.

Grill JD, Cummings JL.

Expert Rev Neurother. 2010 May;10(5):711-28. doi: 10.1586/ern.10.29. Review.

2.

Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.

Serrano-Pozo A, William CM, Ferrer I, Uro-Coste E, Delisle MB, Maurage CA, Hock C, Nitsch RM, Masliah E, Growdon JH, Frosch MP, Hyman BT.

Brain. 2010 May;133(Pt 5):1312-27. doi: 10.1093/brain/awq056. Epub 2010 Mar 31.

3.

Mechanism-based treatments for Alzheimer's disease.

Davies P, Koppel J.

Dialogues Clin Neurosci. 2009;11(2):159-69. Review.

4.

Pharmacotherapeutic targets in Alzheimer's disease.

Biran Y, Masters CL, Barnham KJ, Bush AI, Adlard PA.

J Cell Mol Med. 2009 Jan;13(1):61-86. doi: 10.1111/j.1582-4934.2008.00595.x. Epub 2008 Nov 18. Review.

5.

[Therapy of Alzheimer disease].

Kovács T.

Neuropsychopharmacol Hung. 2009 Mar;11(1):27-33. Review. Hungarian.

6.

Alzheimer's disease.

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.

Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Review.

PMID:
23225010
7.

The molecular pathology of Alzheimer's disease.

Harrington CR.

Neuroimaging Clin N Am. 2012 Feb;22(1):11-22, vii. doi: 10.1016/j.nic.2011.11.003. Review.

PMID:
22284730
8.

Therapeutic strategies for Alzheimer's disease.

Barten DM, Albright CF.

Mol Neurobiol. 2008 Apr-Jun;37(2-3):171-86. doi: 10.1007/s12035-008-8031-2. Epub 2008 Jun 26. Review.

PMID:
18581273
9.

The pulse of drug development for Alzheimer's disease.

Rafii MS.

Rev Recent Clin Trials. 2010 Jan;5(1):57-62. Review.

PMID:
20205688
10.

β-Secretase-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and β-amyloid accumulation.

Cai Y, Xiong K, Zhang XM, Cai H, Luo XG, Feng JC, Clough RW, Struble RG, Patrylo PR, Chu Y, Kordower JH, Yan XX.

Eur J Neurosci. 2010 Oct;32(7):1223-38. doi: 10.1111/j.1460-9568.2010.07376.x. Epub 2010 Aug 18.

11.

APP/PS1 mice overexpressing SREBP-2 exhibit combined Aβ accumulation and tau pathology underlying Alzheimer's disease.

Barbero-Camps E, Fernández A, Martínez L, Fernández-Checa JC, Colell A.

Hum Mol Genet. 2013 Sep 1;22(17):3460-76. doi: 10.1093/hmg/ddt201. Epub 2013 May 6.

12.

Strategies, development, and pitfalls of therapeutic options for Alzheimer's disease.

Haas C.

J Alzheimers Dis. 2012;28(2):241-81. doi: 10.3233/JAD-2011-110986. Review.

PMID:
21987594
13.

Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease.

Barage SH, Sonawane KD.

Neuropeptides. 2015 Aug;52:1-18. doi: 10.1016/j.npep.2015.06.008. Epub 2015 Jul 2. Review.

PMID:
26149638
14.

Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.

Panza F, Solfrizzi V, Frisardi V, Imbimbo BP, Capurso C, D'Introno A, Colacicco AM, Seripa D, Vendemiale G, Capurso A, Pilotto A.

Aging Clin Exp Res. 2009 Dec;21(6):386-406. Review.

PMID:
20154508
15.

Potential therapeutic implications of gelsolin in Alzheimer's disease.

Ji L, Zhao X, Hua Z.

J Alzheimers Dis. 2015;44(1):13-25. doi: 10.3233/JAD-141548. Review.

PMID:
25208622
16.

[Molecular principles of tau-induced toxicity: new experimental therapy strategies for treatment of Alzheimer's disease].

Schneider A, Falkai P, Papassotiropoulos A.

Nervenarzt. 2010 Nov;81(11):1289-90, 1292, 1294, passim. doi: 10.1007/s00115-010-3052-2. German.

PMID:
20842339
17.

Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease.

León R, Garcia AG, Marco-Contelles J.

Med Res Rev. 2013 Jan;33(1):139-89. doi: 10.1002/med.20248. Epub 2011 Jul 26. Review.

PMID:
21793014
18.

Tau therapeutics for Alzheimer's disease: the promise and the challenges.

Gold M.

J Mol Neurosci. 2002 Dec;19(3):331-4. Review.

PMID:
12540060
19.

Targeting nascent soluble Aβ42 for potential Alzheimer drug development.

Zhang M, Hausmann L, Song W.

J Neurochem. 2013 May;125(3):329-31. doi: 10.1111/jnc.12156. Epub 2013 Feb 13. No abstract available.

20.

Zileuton improves memory deficits, amyloid and tau pathology in a mouse model of Alzheimer's disease with plaques and tangles.

Chu J, Li JG, Praticò D.

PLoS One. 2013 Aug 7;8(8):e70991. doi: 10.1371/journal.pone.0070991. eCollection 2013.

Supplemental Content

Support Center